Literature DB >> 28950240

Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.

Kirsten Elin Smith1, Thomas Lawson2.   

Abstract

BACKGROUND: Kratom use in the West has increased recently, yet the prevalence and motives for use among individuals with a history of substance use disorder (SUD) have not been fully examined. Kratom has been documented as a means of treating chronic pain, mitigating drug dependence, and easing withdrawal symptoms, yet it is unclear if substance users are utilizing kratom as a self-medication. Abuse liability, side effects, and overall appeal of kratom remain uncertain.
METHODS: In April 2017, an anonymous survey regarding kratom use and motivations was completed by clients enrolled in a 12-Step-oriented residential program. 500 respondents with a self-reported history of SUD completed the survey.
RESULTS: 20.8% of respondents endorsed lifetime kratom use and 10.2% reported past-12-month use. Kratom-users were younger (=32.1 vs. 35.9, p<0.001) and were more versatile substance users. A majority (68.9%) of kratom-users reported having used the drug as a means of reducing or abstaining from non-prescription opioids (NPO) and/or heroin, and 64.1% reported using kratom as a substitute for NPO/heroin. 18.4% of kratom-users reported using the drug due to a disability or chronic pain. One-third of kratom-users stated that kratom was a helpful substance and that they would try it again. However, kratom was not preferred and was indicated as having less appeal than NPO, heroin, amphetamines, and Suboxone.
CONCLUSIONS: Among substance users, kratom use may be initiated for a variety of reasons, including as a novel form of harm-reduction or drug substitution, particularly in the context of dependence and withdrawal from other substances.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Emerging drugs; Harm-reduction; Kratom; Mitragyna speciosa; Opioid

Mesh:

Substances:

Year:  2017        PMID: 28950240     DOI: 10.1016/j.drugalcdep.2017.08.034

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  28 in total

Review 1.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

2.  Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.

Authors:  Albert Garcia-Romeu; David J Cox; Kirsten E Smith; Kelly E Dunn; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2020-02-03       Impact factor: 4.492

3.  Abuse liability of mitragynine assessed with a self-administration procedure in rats.

Authors:  Kai Yue; Theresa A Kopajtic; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2018-07-23       Impact factor: 4.530

4.  Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Authors:  Kirsten E Smith; Martha D Tillson; Michele Staton; Erin M Winston
Journal:  Drug Alcohol Depend       Date:  2020-01-09       Impact factor: 4.492

5.  Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.

Authors:  Kai Yue; Jonathan L Katz; Xiji Shu
Journal:  Psychopharmacology (Berl)       Date:  2022-02-02       Impact factor: 4.530

6.  Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey.

Authors:  Rhiannon Bath; Tanner Bucholz; Amy F Buros; Darshan Singh; Kirsten E Smith; Charles A Veltri; Oliver Grundmann
Journal:  J Addict Med       Date:  2020 May/Jun       Impact factor: 4.647

7.  Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample.

Authors:  Joseph J Palamar
Journal:  Am J Prev Med       Date:  2021-04-29       Impact factor: 6.604

8.  When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.

Authors:  Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein
Journal:  Am J Drug Alcohol Abuse       Date:  2021-04-28       Impact factor: 3.912

9.  Prevalence of Kratom Use and Co-Occurring Substance Use Disorders in the United States.

Authors:  Kevin Y Xu; Carrie M Mintz; Jacob T Borodovsky; Paul E A Glaser; Laura J Bierut; Richard A Grucza
Journal:  Prim Care Companion CNS Disord       Date:  2021-08-05

10.  Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Destiny Schriefer; Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.